TRAIL is a promising anticancer agent, capable of inducing apoptosis in a wide range of treatment-resistant tumor cells. In 'type II' cells, the death signal triggered by TRAIL requires amplification via the mitochondrial apoptosis pathway. Consequently, deregulation of the intrinsic apoptosis-signaling pathway, for example, by loss of Bax and Bak, confers TRAIL-resistance and limits its application. Here, we show that despite resistance of Bax/Bak double-deficient cells, TRAIL-treatment resulted in caspase-8 activation and complete processing of the caspase-3 proenzymes. However, active caspase-3 was degraded by the proteasome and not detectable unless the XIAP/proteasome pathway was inhibited. Direct or indirect inhibition of XIAP by RNAi, Mithramycin A or by the SMAC mimetic LBW-242 as well as inhibition of the proteasome by Bortezomib overcomes TRAILresistance of Bax/Bak double-deficient tumor cells. Moreover, activation and stabilization of caspase-3 becomes independent of mitochondrial death signaling, demonstrating that inhibition of the XIAP/proteasome pathway overcomes resistance by converting 'type II' to 'type I' cells. Our results further demonstrate that the E3 ubiquitin ligase XIAP is a gatekeeper critical for the 'type II' phenotype. Pharmacological manipulation of XIAP therefore is a promising strategy to sensitize cells for TRAIL and to overcome TRAIL-resistance in case of central defects in the intrinsic apoptosis-signaling pathway. Subject Category: Cancer TRAIL (tumor necrosis factor-related apoptosis-inducing ligand/Apo2L) is capable of inducing cell death in a wide range of cancers resistant to conventional therapy without apparent toxic side effects to normal tissues. 1 The expression of TRAIL-R1 is an independent prognostic parameter, for example, in colon carcinoma and high expression of TRAIL-R1 correlates with prolonged disease-free survival.
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand/Apo2L) is capable of inducing cell death in a wide range of cancers resistant to conventional therapy without apparent toxic side effects to normal tissues. 1 The expression of TRAIL-R1 is an independent prognostic parameter, for example, in colon carcinoma and high expression of TRAIL-R1 correlates with prolonged disease-free survival. 2 Furthermore, TRAIL and the death ligands CD95L/FasL and TNFa sensitize tumor cells for ionizing radiation-and drug-induced apoptosis 3, 4 albeit toxicity profiles may hamper (TNFa) or even preclude (CD95L/FasL) clinical use.
Death ligands initiate receptor oligomerization and formation of the death inducing signaling complex (DISC), resulting in activation of the initiator caspase-8. In type I cells, active caspase-8 directly mediates sufficient activation of the effector caspase-3 that triggers execution of apoptosis. In contrast, in type II cells, the death signal requires amplification via activation of the intrinsic cell death pathway 5 through caspase-8-mediated cleavage and activation of Bid, a BH3-only protein of the Bcl-2 family. 6 Thus, proteins of the Bcl-2 family are key regulators of both mitochondrial and death receptor-mediated apoptosis. Members of the family show homology in at least one of the four Bcl-2 homology (BH) domains. Anti-apoptotic proteins of this family (Bcl-2, Bcl-x L Bcl-w, Mcl-1 and Bfl-1/A1) are characterized by the presence of all four BH domains. Pro-apoptotic members can be subdivided into the multidomain BH123 homologs (Bax and Bak), and the proteins of the BH3-only subfamily (Bad, Bim, Puma, Noxa, Nbk/Bik, Bmf, Bnip3, Hrk and Bid).
IAPs, a family of eight human analogs including cIAP1, cIAP2 and XIAP, the latter the most potent one, 10 prevent inadvertent caspase activation XIAP does this by binding directly to caspases through its baculovirus IAP repeat (BIR) domain. Many human tumors express high levels of IAPs including XIAP and aberrant expression of IAPs has been linked to therapy resistance and poor prognosis. 11 In addition to the upregulation of XIAP, deregulation of pro-and anti-apoptotic Bcl-2 family proteins is a central mechanism involved in TRAIL-resistance. 12, 13 We have recently shown that loss of Bax, despite expression of its homolog Bak, confers resistance to TRAIL-induced apoptosis. However, inhibition of the endogenous Bak antagonist Mcl-1 enables TRAIL to kill cells via Bak. 14 Here, we show that inhibition of the XIAP/proteasome pathway renders Bax/Bak double-deficient carcinoma cells sensitive to TRAIL. Because mitochondrial amplification of the death receptor signal is impossible in these cells, downregulation of XIAP converts type II into type I cells. These results show that in TRAIL-induced apoptosis, XIAP dictates the type II mode of cell death and that switching the cell death mode is a promising strategy to overcome TRAIL-resistance in cells with central defects in mitochondrial apoptosis signaling.
Results
To evaluate strategies to overcome resistance to TRAIL, we addressed the role of XIAP in a HCT116 colon cancer cell line model. We compared the impact of Mcl-1 and XIAP downregulation on TRAIL-treated isogenic HCT116 wt cells, HCT116 Bax-deficient cells (termed HCT116 Bax À ) and cells devoid of Bax and Bak (termed HCT Bax À /Bak À ). 15 Specific loss of protein expression was achieved by knockout of bax 16 and stable shRNA-mediated Bak knockdown 17 and was verified by western blot analysis (Figures 1a and c can be compared because they represent the same membranes).
HCT116 cells were transfected with control-, Mcl-1-or XIAP-siRNA and downregulation of the respective proteins was confirmed by western blot analysis (figure1, left). Upon downregulation of Mcl-1 or XIAP, cells were incubated with 50 ng/ml TRAIL for 24 h and induction of apoptosis was analyzed by flow cytometric measurement of cells with a hypodiploid DNA content. TRAIL-treatment resulted in apoptotic DNA fragmentation in about 28% of the HCT116 wt cells. Sensitivity toward TRAIL was increased by knockdown of Mcl-1 and even more by XIAP knockdown, about 35 and 42% of the respective cells were apoptotic (Figure 1a, right) .
Unlike HCT116 wt cells, Bax-deficient HCT116 cells were resistant to TRAIL-induced apoptosis. However, Mcl-1 or XIAP downregulation rendered these cells susceptible to TRAIL. Compared with 6% of control cells, TRAIL-induced apoptosis increased up to 32 and 41% upon Mcl-1 or XIAP downregulation, respectively (Figure 1b, right) .
In contrast, TRAIL-resistance of HCT116 Bax À /Bak À cells could not be overcome by inhibition of Mcl-1. However, downregulation of XIAP strongly sensitized these doubledeficient cells for TRAIL-induced apoptosis. Cells transfected with control-or Mcl-1-siRNA and treated with TRAIL showed apoptotic DNA fragmentation in o6% of the cells, which increased to 34% upon XIAP downregulation (Figure 1c, right) .
Annexin V-FITC/propidium iodide (PI) staining of HCT116 wt and HCT116 Bax À /Bak À cells upon TRAIL-treatment confirmed that cell death occurs by apoptosis and that TRAILresistance of HCT116 Bax À /Bak À cells can be overcome by downregulation of XIAP (Supplementary Figure S1) . Furthermore, XIAP downregulation overrides resistance of Bcl-2 or Bcl-x L overexpressing HCT116 cells, supporting our finding that upon TRAIL-treatment XIAP-deficient cells die independently of a Bcl-2 family protein regulated pathway (Supplementary Figure S2) .
As caspase-8 and -3 are crucial for TRAIL-induced apoptosis, we next examined to which extent Bax/Bak deficiency impacts on processing of caspase-8 and -3. We treated HCT116 wt and Bax À /Bak À cells with TRAIL and analyzed the cleavage pattern of these caspases. Procaspase-8 and -3 levels are comparable in both cell lines, respectively (Figure 2a, left) . Following TRAIL-treatment, procaspase-8 is cleaved in both cell lines and processed to its active subunits to a similar extent. Interestingly, in both cell lines, caspase-8 activation goes along with cleavage of the pro-caspase-3 zymogen, indicating that caspase-8 activation upon TRAIL-treatment is sufficient to cleave pro-caspase-3. Nevertheless, cleavage of pro-caspase-3 is accompanied by processing to its active p18/p16 subunits only in TRAILsensitive HCT116 wt cells. In contrast, TRAIL-resistant HCT116 Bax À /Bak À cells showed no processing of caspase-3 to its active subunits (Figure 2a, left) . Thus, in contrast to cleavage of the pro-caspase-3 zymogen, which is independent of Bax and Bak, processing of pro-caspase-3 to its active subunits relies on an intact intrinsic mitochondrial pathway.
To analyze if the ubiquitin ligase activity of XIAP mediates degradation of the caspase-3 subunits we knocked down XIAP. In HCT116 Bax À /Bak À cells transfected with control siRNA, TRAIL-treatment resulted in pro-caspase-3 cleavage without generation of the active caspase-3. In contrast, downregulation of XIAP in combination with TRAIL caused full processing of pro-caspase-3 to its active subunits (Figure 2a, right) . This indicates that caspase-8 activity triggered by TRAIL is sufficient to cleave pro-caspase-3 while caspase-3 activation is prevented by XIAP-mediated degradation of processed caspase-3.
To investigate proteasomal degradation of active caspase-3, we treated HCT116 wt and Bax À /Bak À cells with non-toxic concentrations of the proteasome inhibitor MG132. In HCT116 wt cells, TRAIL-induced caspase-3 activation is increased upon additional treatment with MG132 (Figure 2b , left). More importantly, in HCT116 Bax À /Bak À cells, TRAIL alone induced the cleavage of pro-caspase-3 without detectable levels of active subunits, whereas the combination induced full caspase-3 processing to its active subunits (Figure 2b, right) .
In agreement with increased caspase-3 activation, TRAILinduced apoptosis was increased in HCT116 wt cells upon additional inhibition of the proteasome. Moreover, MG132 treatment overcame TRAIL-resistance of Bax/Bax À deficient HCT116 cells (Figure 2c ). Like MG132, bortezomib (BZM), the first therapeutic proteasome inhibitor, sensitized HCT116 wt cells for TRAIL-induced apoptosis and overcame TRAILresistance of HCT116 Bax À /Bak À cells (Figure 2d ), indicating that sensitization towards TRAIL-induced apoptosis by inhibition of the proteasome is caused by stabilization of active caspase-3 and does not rely on the intrinsic apoptotic pathway.
To further investigate the mode of caspase-3 activation in the presence or absence of XIAP in relation to type I/II apoptosis signaling, we analyzed TRAIL-induced apoptosis in cells subjected to caspase-8 and Bid downregulation. In HCT116 wt cells, TRAIL-induced apoptosis was accompanied by pro-caspase-8 processing, Bid cleavage and processing of pro-caspase-3 to active subunits ( Figure 3a) . Downregulation of caspase-8 or Bid inhibited induction of apoptosis. But in contrast to caspase-8 downregulation, which blocked TRAILinduced pro-caspase-3 cleavage, Bid knockdown did not impair pro-caspase-3 cleavage, indicating that most of the detected pro-caspase-3 processing occurs upstream of the mitochondrial amplification loop. However, although procaspase-3 was cleaved, subunits were decreased after Bid downregulation (Figure 3a , right), indicating that processing of pro-caspase-3 to the active subunits depends on Bid.
Additional knockdown of XIAP restored the induction of apoptosis by TRAIL in HCT116 wt cells with Bid knockdown (Figure 3b , left) and resulted in complete cleavage of procaspase-8 and pro-caspase-3, accompanied by high levels of the p18 caspase-3 subunit (Figure 3b To analyze dissipation of mitochondrial membrane potential (DC m ) upon TRAIL-treatment, cells were incubated with the fluorochrome JC-1, which exhibits membrane potentialdependent accumulation in mitochondria. Measurement of JC-1-fluorescence intensity by flow cytometry showed a timedependent accumulation of HCT116 wt cells with disruption of DC m upon TRAIL-treatment. This was an early event detectable already after 6 h of treatment that precedes DNA fragmentation (Figure 4b, left) .
In analogy, HCT116 Bax À /Bak À cells with downregulated XIAP showed caspase-8 and Bid processing as early events during TRAIL-induced apoptosis, detectable 4 h after treatment. In contrast to HCT116 wt cells, Bid cleavage did, however, not coincide with cytochrome c or SMAC release. Both occurred only late upon TRAIL-treatment, detectable (Figure 4a, right) . This indicates that tBid failed to trigger the mitochondrial pathway. Nevertheless, TRAILtreatment in the absence of XIAP resulted in early caspase-3 activation, which coincided with PARP cleavage (Figure 4a , right). Furthermore, despite early induction of apoptosis but in line with the delayed kinetic of cytochrome c and SMAC release, MMP was also a late event in these cells. Interestingly, and in contrast to HCT116 wt cells, breakdown of DC m followed DNA fragmentation upon TRAIL-treatment in HCT116 Bax À /Bak À cells (Figure 4b, right) , indicating that MMP occurs late and coincides with cellular demise instead of playing an early, regulatory role. In summary, XIAP downregulation facilitates TRAIL-induced apoptosis signaling that is independent of MMP, cytochrome c and SMAC release, which all seem to be secondary effects.
Time response analysis of Annexin V-FITC/PI staining upon TRAIL-treatment confirms the different cell death mode. Figure S3) . Interestingly at this time point, HCT116 Bax À /Bak À cells also display MMP and cytochrome c release (Figures 4a and b) . Taken together, the results indicate that MMP and cytochrome c release, which occur early in type II and late in type I cells, are accompanied by a late apoptotic/necrotic phenotype of the cells.
Given the therapeutic impact of our findings, we next asked if small molecules, known to downregulate or inhibit XIAP, can overcome the resistance of Bax/Bak-deficient cells. The antitumor agent Mithramycin A (Mit A) sensitizes various cancer cell lines to TRAIL-mediated apoptosis by downregulation of XIAP. 19 To confirm downregulation of XIAP by Mit A, we treated HCT116 wt and HCT116 Bax À /Bak À cells with different concentrations of Mit A for 24 h. Subsequent analysis of XIAP levels confirmed reduced XIAP expression (Figure 5a ). This is accompanied by an increased TRAIL sensitivity in HCT116 wt cells, mainly due to Bax/Bakdependent, additive toxicity of Mit A. Furthermore, Mit A treatment efficiently overcame TRAIL-resistance of Bax/Bakdeficient HCT116 cells (Figure 5a, lower panel) .
Additionally, we targeted XIAP directly by use of the SMAC mimetic LBW-242, a synthetic small molecule that binds to and inhibits IAPs. Treatment of HCT116 cells with LBW-242 in addition to TRAIL reduced XIAP expression (Figure 5b , upper panel, lanes 2 and 4), which might be due to cleavage of XIAP by caspase-3 in a feedback loop or autoubiquitylation and proteasomal degradation. Furthermore, inhibition of XIAP resulted in an increase of TRAIL-induced apoptosis To analyze if XIAP plays a similar role in cell death induced by other death receptors, we treated cells with TNFa or CD95L/FasL. In HCT116 wt cells, TNFa treatment resulted in weak induction of apoptosis; B10% of the cells were apoptotic (Figure 6a) . Compared with TNFa, CD95L/FasLinduced DNA fragmentation was more pronounced and 24% of the cells underwent apoptosis. However, upon XIAP downregulation TNFa as well as CD95L/FasL-induced apoptosis was increased up to 16% and 37%, respectively. In contrast to HCT116 wt cells, neither TNFa nor CD95L/FasL induced apoptosis in HCT116 Bax À /Bak À cells. However, resistance was overcome by XIAP downregulation, resulting in around 17% and 25% apoptotic cells upon TNFa or CD95L/ FasL treatment, respectively (Figure 6b) . Altogether, these data show that downregulation of XIAP enables death Figure 3 Upon XIAP silencing, TRAIL-induced apoptosis and caspase-3 activation become independent of Bid, Bax and Bak. (a) HCT116 wt cells were transfected with control-, caspase-8-or Bid-siRNA and subsequently incubated with TRAIL. TRAIL-induced DNA fragmentation was blocked by downregulation of either caspase-8 or Bid (left). Western blot analysis confirmed downregulation of the respective proteins (right). Furthermore, western blot analysis showed that knockdown of caspase-8 blocked pro-caspase-3 cleavage. In contrast, knockdown of Bid did not inhibit pro-caspase-3 cleavage but processing of caspase-3 to its active subunits. (b) HCT116 wt were treated as in (a). In addition, XIAP was knocked down. Upon XIAP knockdown, TRAIL-induced apoptosis was inhibited by caspase-8 downregulation but not anymore by Bid downregulation (left). In this setting, TRAIL-induced activation of pro-caspase-3, indicated by the active subunit, depends on caspase-8 but was independent of Bid. (c) HCT116 Bax À /Bak À cells were treated as in (b). Upon XIAP downregulation, TRAIL-induced apoptosis (left) is accompanied by caspase-3 activation (right). Both can be blocked by knockdown of caspase-8. In contrast, caspase-3 activation and apoptosis was not blocked by downregulation of Bid. Thus, inhibition of XIAP enables TRAIL to activate caspase-3 and to induce apoptosis despite combined loss of Bid, Bax and Bak receptors to kill type II cells independently of the mitochondrial death machinery by switching the apoptotic-signaling pathway from type II to type I.
Discussion
Strategies to overcome TRAIL-resistance comprise inhibition of pro-survival signaling, for example, the NF-kB pathway, 20 inhibition of the proteasome 21 or inhibition of histone deacetylases. 22 The kinase inhibitors Roscovitine or Sorafenib sensitize cancer cells to TRAIL through pleiotropic mechanisms comprising facilitated DISC formation and caspase-8 activation, downregulation of cFLIP and XIAP and suppression of Mcl-1. 14, 23, 24 Strategies directly targeting the Bcl-2 family include BH3 mimetics like ABT-737 that bind to the hydrophobic groove exposed at the surface of antiapoptotic proteins, block their pro-survival function and potentiate TRAIL-mediated apoptosis. 25 However, cell death still relies on the presence of Bax and Bak as MMP mediators. Inhibition of IAPs is another promising approach to sensitize treatment-resistant tumor cells for TRAIL. Especially the inhibition of XIAP by small molecular SMAC mimetics has been shown to synergize with TRAIL and to potentiate TRAIL-induced apoptosis in various cancer cells. 26, 27 We addressed not only the role but also the pharmacological targeting of XIAP in type I/II signaling. In contrast to type I cells, type II cells require activation of a mitochondrial amplification loop to achieve full caspase activation that depends on activation of Bid. Interestingly, a recent report showed that loss of XIAP alleviates the need for Bid in CD95/ Fas-induced hepatocyte apoptosis in mice. 28 Here, we show that TRAIL-resistance of type II carcinoma cells with central mitochondrial death signaling defects was overcome by inhibition of XIAP. This enabled TRAIL to induce apoptosis in cells overexpressing the anti-apoptotic proteins Bcl-2 or Bcl-x L or in cells deficient for the pro-apoptotic proteins Bax, Bak, and Bid. Under these conditions, apoptosis is not accompanied by MMP and cytochrome c or SMAC release, indicating that cell death induction is independent of the intrinsic pathway. This is in contrast to Bax/Bak positive cells, where MMP and cytochrome c release precedes apoptosis. Thus, downregulation of XIAP bypasses a cell death blockade at the level of the mitochondria by switching apoptosis signaling from type II to type I. This observation significantly extends other studies that identified the level of caspase-8 activation upon death receptor activation as critical discriminator between type I/II apoptosis signaling. 5 According to this model, type I cells display strong activation of caspase-8 upon death receptor ligation to directly activate caspase-3, thereby bypassing the mitochondria. In contrast, type II cells would generate only low amounts of active caspase-8 at the DISC and strong activation of caspase-3 occurs at a level secondary to mitochondrial events. However, in HCT116 cells caspase-8 activation induced by TRAIL is sufficient to cleave pro-caspase-3 regardless of loss of Bax/ Bak expression. Nevertheless, pro-caspase-3 is processed to its active subunits only in cells with an intact mitochondrial apoptotic-signaling pathway. In the absence of MMP, caspase-3 subunits were degraded by the XIAP/ proteasome pathway. Upon activation of the mitochondria through Bax/Bak, SMAC, released into the cytosol, inhibits XIAP and prevents degradation of caspase-3 subunits resulting in strong caspase-3 activation (Figure 7) . Consequently, inhibition of XIAP enables caspase-8 to directly induce sufficient amounts of active caspase-3 in Bax/Bak-deficient HCT116 cells thereby making SMAC release dispensable.
Taken together, we demonstrate that it is not the extent of active caspase-8 but the activity of XIAP, which makes a distinction between cell death induction via a type II or type I pathway.
Pharmacological targeting of this type I/II switch would overcome the need for Bax/Bak proficiency. In this vein, we show that processing of pro-caspase-3 to its active subunits without activation of the mitochondria can be enforced by inhibition of the proteasome. Proteasome inhibitors may sensitize tumor cells for TRAIL by enhanced cell surface expression of TRAIL-R1 (DR4) and TRAIL-R2 (DR5), enhanced activation of the initiator caspase-8 and downregulation of cFLIP. 29, 30 Furthermore, bortezomib-induced stabilization of the Bax protein as well as increased levels of Nbk/Bik and Bim were implicated in sensitization for TRAIL killing. 31, 32 Our data suggest that the stabilization of active caspase-3 by blocking its proteasomal degradation, by either inhibiting proteasomal activity or preventing XIAP-mediated ubiquitylation, is the main mechanism responsible for sensitization. Interestingly, the caspase-3 fragments, which accumulate upon proteasome inhibition in addition to TRAILtreatment, seem to be unubiquitinated (Figure 2a) . Caspases have been shown to inhibit XIAP by cleavage 33 and this Here, we show that LBW-242 overcomes resistance of Bax/ Bak-deficient cancer cells and re-sensitizes these cells to TRAIL. Loss of both Bax or Bak expression has been reported for a number of tumors. [36] [37] [38] [39] Whereas loss of Bax is a frequent event in human cancer, for example, in colon cancers having a microsatellite mutator phenotype, Bak expression persists in most cancers and loss of both is a rare event. Notably, loss of Bax, despite expression of Bak, is sufficient for tumor cells to acquire TRAIL-resistance. In addition, the intrinsic apoptotic pathway of tumor cells can be blocked by other mechanisms, for example, upregulation of Bcl-x L (which efficiently inhibits both, Bax and Bak) or endogenous Bak-inhibitors Mcl-1 or VDAC2 in Bax-deficient carcinoma. 14, 15, 40 The data presented in this study indicate that use of SMAC mimetics is a suitable strategy to antagonize therapy resistance caused by all these central defects in the intrinsic apoptosis machinery and delineates the combined use of TRAIL together with SMAC mimetics as a useful strategy. Altogether, these data show that targeting of XIAP enables death receptor signaling to kill type II cells via a type I pathway and define XIAP as a crucial decision point between these two cell death pathways.
Immunoblotting. After trypsination, cells were washed twice with ice-cold PBS and lysed in 10 mM Tris-HCl pH 7.5, 137 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM pepstatin, 1 mM leupeptin and 0.1 mM phenylmethyl sulfonylfluoride (PMSF). Protein concentration was determined using the bicinchoninic acid assay. Equal amounts of protein were separated by SDS-PAGE, electroblotted and visualized as described. 41 For analysis of cytochrome c and SMAC release, cytosolic extracts were prepared according to a method described previously. 41 Briefly, after induction of apoptosis, cells were harvested in PBS, equilibrated in hypotonic buffer (20 mM HEPES pH 7.4, 10 mM KCl, 2 mM MgCl 2 , 1 mM EDTA) supplemented with 0.1 mM PMSF and 0.75 mg/ml digitonin (Sigma-Aldrich) and incubated on ice for 3 min. Debris was pelleted by centrifugation at 10 000 Â g at 4 1C for 5 min and the supernatant was subjected to western blot analysis.
Measurement of mitochondrial permeability transition. Cells were harvested and collected by centrifugation at 300 Â g at 4 1C for 5 min. Mitochondrial permeability transition was determined by staining the cells with JC-1 (5, 5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethyl-benzimidazolylcarbocyanin iodide; Molecular Probes, Leiden, The Netherlands), a cationic dye that exhibits membrane potential-dependent accumulation in mitochondria, as described. 41 Mitochondrial permeability transition was then quantified by flow cytometric determination of cells with decreased red fluorescence, that is, with mitochondria displaying a reduced membrane potential (DC m ).
Measurement of apoptotic cell death by flow cytometry. DNA fragmentation was measured as described. 15 Briefly, cells were collected by centrifugation at 300 Â g for 5 min, washed with PBS at 4 1C, and fixed in PBS/2% (vol/vol) formaldehyde on ice for 30 min. After fixation, cells were incubated with ethanol/PBS (2 : 1, vol/vol) for 15 min, pelleted, and resuspended in PBS containing 40 mg/ml RNase A. After incubation for 30 min at 37 1C, cells were pelleted and finally resuspended in PBS containing 50 mg/ml PI. DNA fragmentation was quantified by flow cytometric determination of hypodiploid DNA. Data were collected and analyzed using a FACScan (Becton Dickinson, Heidelberg, Germany) equipped with the CELLQuest software. Data are given in % hypoploidy (subG1), which reflects the number of apoptotic cells. Alternatively, cell death was determined by staining cells with Annexin V-fluorescein isothiocyanate (FITC) and counterstaining with PI. 15 Briefly, cells were washed twice with cold PBS and resuspended in 10 mM N- [2-hydroxyethyl] piperazin-N 0 -3[propansulfonicacid]/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 at 1 Â 10 6 cells/ml. Next, 5 ml of Annexin V-FITC (BD PharMingen, Heidelberg, Germany) and 10 ml PI (20 g/ml, Sigma-Aldrich) were added. Analyses were performed using a FACScan (Becton Dickinson) and CELLQuest analysis software. Results are given in % of cells.
